Kura Oncology (NASDAQ:KURA) Raised to “Strong-Buy” at Cantor Fitzgerald
Kura Oncology (NASDAQ:KURA – Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports. Several other research firms have also recently commented on KURA. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Kura Oncology […]
